2020
Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer
Chobrutskiy A, Chobrutskiy BI, Zaman S, Hsiang M, Blanck G. Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer. Breast Cancer Research And Treatment 2020, 185: 591-600. PMID: 33180235, DOI: 10.1007/s10549-020-05996-6.Peer-Reviewed Original ResearchConceptsOverall survivalBreast cancerPrimary breast cancer patientsGamma delta T cellsBreast cancer tumor tissuesBreast cancer settingProgesterone receptor statusBreast cancer patientsGreater overall survivalPotential antigenic targetsCancer tumor tissuesPatient ageReceptor statusCancer patientsAntigenic targetsCancer settingT cellsSurvival correlationB cellsSurvival rateTumor tissueHigher survival rateImmunogenomic approachesConclusionsThese resultsSurvival parameters
2019
Targeting Trop-2 in solid tumors: future prospects
Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. OncoTargets And Therapy 2019, 12: 1781-1790. PMID: 30881031, PMCID: PMC6402435, DOI: 10.2147/ott.s162447.Peer-Reviewed Original ResearchAntibody-drug conjugatesTrop-2Clinical benefitClinical trialsTumor typesPlatinum-resistant urothelial cancerSmall cell lung cancerMultiple early-phase clinical trialsTriple-negative breast cancerEarly phase clinical trialsLimited treatment optionsTrop-2 expressionMultiple tumor typesUrothelial cancerTreatment optionsLung cancerBreast cancerSolid tumorsBaseline levelsCancer typesClinical useUpregulated expressionCancerTumorsNormal cells
2018
MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma
Zaman S, Chobrutskiy BI, Sikaria D, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma. Oncology Reports 2018, 41: 1359-1366. PMID: 30535461, DOI: 10.3892/or.2018.6896.Peer-Reviewed Original ResearchMAPT expressionSurvival rateΑ-synuclein gene expressionDisease-free survivalCentral nervous systemLow-grade gliomasAssociation of MAPTRate of survivalCancer Genome AtlasBreast cancerNeurodegenerative roleTau expressionBrain cancerNervous systemNeurological disordersTau proteinMAPT geneHigh expressionCancerGenome AtlasPrecursor proteinExpression levelsSuch associationsSurvivalTauClinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy.
Anderson M, Denson A, Zaman S, Han H, Soliman H. Clinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy. JCO Precision Oncology 2018, 2: 1-5. PMID: 35135142, DOI: 10.1200/po.18.00123.Peer-Reviewed Original ResearchImmune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates
Tong WL, Callahan BM, Tu YN, Zaman S, Chobrutskiy BI, Blanck G. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Research And Treatment 2018, 173: 167-177. PMID: 30229447, DOI: 10.1007/s10549-018-4961-1.Peer-Reviewed Original ResearchConceptsImmune receptor recombinationsSpecific HLA allelesExome filesHLA typesBreast cancerHLA allelesSurvival rateImmune checkpoint inhibitor therapyImproved disease-free survivalDisease-free outcomeCheckpoint inhibitor therapyT cell receptor VUse of immunotherapyDisease-free survivalSegment usageB cell biomarkersBreast cancer subgroupsHLA allele combinationsBetter survival rateBreast cancer samplesBreast tumor samplesGene segment usageSurvival distinctionsInhibitor therapyImmune characterization